Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.96 USD
+0.04 (1.37%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.89 -0.07 (-2.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Lisata Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
LSTA 2.96 +0.04(1.37%)
Will LSTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
Other News for LSTA
Lisata Therapeutics Q2 2025 Earnings Preview
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business ...
12 Health Care Stocks Moving In Monday's Pre-Market Session
LSTA Shows Promising Results in Latest iLSTA Trial | LSTA Stock News
Lisata Therapeutics (LSTA) Completes Enrollment for Pancreatic Cancer Trial | LSTA Stock News